Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06718686 · ClinicalTrials.gov registry record · Phase 1
Rifaximin SSD in Dementia Trial
A Phase 1 study of Dementia Alzheimer Type and Dementia Associated With Cerebrovascular Disease, sponsored by Jasmohan Bajaj.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06718686: Recruiting Phase 1 study of Dementia Alzheimer Type and Dementia Associated With Cerebrovascular Disease, sponsored by Jasmohan Bajaj.
NCT06718686 is a Phase 1 study of Dementia Alzheimer Type and Dementia Associated With Cerebrovascular Disease that is actively recruiting participants, run by Jasmohan Bajaj. The registered enrollment target is 20 participants, below the 73-participant average among 8 other Dementia Alzheimer Type trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06718686, a Phase 1 study of Dementia Alzheimer Type and Dementia Associated With Cerebrovascular Disease, is actively recruiting participants, sponsored by Jasmohan Bajaj.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Using a new formulation of rifaximin, a non-absorbable antibiotic, to test if it can affect microbes in the gut of patients with dementia favorably.
Primary Outcome
Change in SCFA in stool and serum in rifaximin SSD phase vs placebo phase
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rifaximin SSD 40 mg IR tablet
Study Locations (1)
Virginia
- Richmond VA Medical Center - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-12-30 |
| Est. Completion | 2026-05 |
| Phase | Phase 1 |
What NCT06718686 shows while recruiting
NCT06718686 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 73-participant average among 8 other Dementia Alzheimer Type trials with a reported enrollment target (73% lower).
The record links to 2 conditions, with Dementia Alzheimer Type appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06718686 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT06718686 about?
NCT06718686 is a clinical study titled "Rifaximin SSD in Dementia Trial". Using a new formulation of rifaximin, a non-absorbable antibiotic, to test if it can affect microbes in the gut of patients with dementia favorably.
What is the current status of trial NCT06718686?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2024-12-30. Estimated completion is 2026-05.
What conditions does trial NCT06718686 study?
This clinical trial studies the following conditions: Dementia Alzheimer Type, Dementia Associated With Cerebrovascular Disease.
What interventions are being tested in trial NCT06718686?
The interventions under investigation include: Placebo (DRUG), Rifaximin SSD 40 mg IR tablet (DRUG).
Who is sponsoring clinical trial NCT06718686?
This trial is sponsored by Jasmohan Bajaj, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06718686 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dementia Alzheimer Type
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06718686's enrollment target sits among peer trials
20 9th of 8 the lowest of 8 other Dementia Alzheimer Type trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dementia Alzheimer Type trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)
RECRUITING · Phase 1
-
Dynamic Light Scattering Ocular Measurement in the Detection of Dementia
RECRUITING
-
University of Central Florida Music Study
RECRUITING · NA
-
Reducing African Americans' Alzheimer's Disease Risk Through Exercise (RAATE)"
RECRUITING · NA
-
Studies of Brain and Body Interaction
RECRUITING
-
Multi-Center Study of Sensory Stimulation to Improve Brain Function
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI